Generic selection criteria for safety and patient benefit [XII] : Comparing the physicochemical and pharmaceutical properties of brand-name and generic tulobuterol tape

被引:0
|
作者
Shimokawa, Ken-ichi [1 ]
Yotsukura, Kayo [1 ]
Nozawa, Mitsuru [2 ]
Wada, Yuko [3 ]
Ishii, Fumiyoshi [3 ]
机构
[1] Meiji Pharmaceut Univ, Dept Pharmaceut Sci, 2-522-1 Noshio, Kiyose, Tokyo 2048588, Japan
[2] Triad Japan Co Ltd, Sagamihara, Kanagawa, Japan
[3] Meiji Pharmaceut Univ, Dept Selfmedicat & Hlth Care Sci, Tokyo, Japan
关键词
Transdermal therapeutic drug; brand-name drug; generic drug; tulobuterol tape; USABILITY;
D O I
10.5582/ddt.2023.01076
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Physicochemical properties (drug release, peel strength, adhesion, and stiffness) of Hokunalin((R)) Tape (Hokunalin) and 13 generic transdermal bronchodilator patches containing tulobuterol were characterized and evaluated for comparison. Drug-release studies evaluating sustained release behavior demonstrated better performance by the drug Hokunalin, than the generics MED, YP, Sawai, and Teikoku. Hokunalin yield a 16.2% release 1 hour after initiation, 30.1% at 3 hours, 50.0% at 8 hours. In comparison, the generics MED, YP, Sawai, and Teikoku showed an intermediate release behavior to that of Hokunalin, with more than 80% release after 8 hours. A 90-degree peel adhesion test for tape peel strength demonstrated that the generic MED (4.99 N), YP (3.26 N), Sawai (4.17 N), and Teikoku (4.37 N) tapes yielded significantly higher values compared to Hokunalin (2.66 N). Probe tack tests, evaluating adhesive strength, yielded significantly higher values for the generics HMT (4.89 N) and Towa (4.25 N) compared to Hokunalin (3.66 N). Furthermore, for the stiffness-softness test, a significantly higher value was obtained for each generic yielded compared to Hokunalin (3.7-degree). These factors are important components of product qualities that affect treatment efficacy, including "ease of application" and other usability factors.
引用
下载
收藏
页数:6
相关论文
共 45 条
  • [41] Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart
    Kim, Yong Il
    Kim, Jee Hyun
    Lee, Tae Yoon
    Lee, Kyoo Won
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2015, 31 (06) : 335 - 339
  • [42] Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome
    Beksac, Meral
    Seval, Guldane Cengiz
    Koyun, Derya
    Topcuoglu, Pervin
    Yuksel, Meltem-Kurt
    Gurman, Gunhan
    Ilhan, Osman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (03): : E164 - E170
  • [43] Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
    A. Sicras-Mainar
    L. Sánchez-Álvarez
    R. Navarro-Artieda
    J. Darbà
    Lipids in Health and Disease, 17
  • [44] Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
    Sicras-Mainar, A.
    Sanchez-Alvarez, L.
    Navarro-Artieda, R.
    Darba, J.
    LIPIDS IN HEALTH AND DISEASE, 2018, 17
  • [45] Generic selection criteria for safety and patient benefit [IX]: Evaluation of "feeling of use" of sodium hyaluronate eye drops using the Haptic Skill Logger (HapLog®) wearable sensor for evaluating haptic behaviors
    Goto, Miho
    Nozawa, Mitsuru
    Wada, Yuko
    Shimokawa, Ken-ichi
    Ishii, Fumiyoshi
    DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (01): : 14 - 20